An experimental study of VEGF induced changes in vasoactivity in pig retinal arterioles and the influence of an anti-VEGF agent

BMC Ophthalmology

Volumn 12, Issue 1, 2012, Pages

  Su, Er Ning ^a,b   Cringle, Stephen J ^a,b   McAllister, Ian L ^a   Yu, Dao Yi ^a,b  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; ENDOTHELIN 1; VASCULOTROPIN A;

ANIMAL; ANTAGONISTS AND INHIBITORS; ARTERIOLE; CATHETERIZATION; DRUG EFFECTS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MUSCLE CONTRACTION; PHYSIOLOGY; PIG; RETINA ARTERY; VASCULAR SMOOTH MUSCLE; VASODILATATION;

ANGIOGENESIS INHIBITORS; ANIMALS; ARTERIOLES; BEVACIZUMAB; CATHETERIZATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; ENDOTHELIN-1; MUSCLE CONTRACTION; MUSCLE, SMOOTH, VASCULAR; RETINAL ARTERY; SUS SCROFA; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASODILATION;

EID: 84861477961     PISSN: None     EISSN: 14712415     Source Type: Journal    
DOI: 10.1186/1471-2415-12-10     Document Type: Article

References (46)

1. Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis. Connolly DT, Heuvelman DM, Nelson R, Olander JV, Eppley BL, Delfino JJ, et al. J Clin Invest 1989 84 1470 1478 10.1172/JCI114322 2478587 (Pubitemid 19272234)
2. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF, Science 1983 219 983 985 10.1126/science.6823562 6823562
3. Vascular endothelial growth factor induces EDRF-dependent relaxation in coronary arteries. Ku DD, Zaleski JK, Liu S, Brock TA, Am J Physiol 1993 265 586 H592 8368362
4. VEGF improves myocardial blood flow but produces EDRF-mediated hypotension in porcine hearts. Hariawala MD, Horowitz JR, Esakof D, Sheriff DD, Walter DH, Keyt B, et al. J Surg Res 1996 63 77 82 10.1006/jsre.1996.0226 8661176 (Pubitemid 26197723)
5. Pregnancy augments uteroplacental vascular endothelial growth factor gene expression and vasodilator effects. Ni Y, May V, Braas K, Osol G, Am J Physiol 1997 273 938 H944 9277513
6. Vascular endothelial growth factor-mediated endothelium-dependent relaxation is blunted in spontaneously hypertensive rats. Liu MH, Jin HK, Floten HS, Yang Q, Yim AP, Furnary A, et al. J Pharmacol Exp Ther 2001 296 473 477 11160633 (Pubitemid 32112475)
7. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, et al. J Clin Invest 2003 111 649 658 12618519 (Pubitemid 36278583)
8. VEGF receptor signaling and endothelial function. Kliche S, Waltenberger J, IUBMB Life 2001 52 61 66 10.1080/15216540252774784 11795595 (Pubitemid 33769671)
9. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Ferrara N, Henzel WJ, Biochem Biophys Res Commun 1989 161 851 858 10.1016/0006-291X(89)92678-8 2735925 (Pubitemid 19162712)
10. Vascular endothelial growth factor receptor localization and activation in human trophoblast and choriocarcinoma cells. Charnock-Jones DS, Sharkey AM, Boocock CA, Ahmed A, Plevin R, Ferrara N, et al. Biol Reprod 1994 51 524 530 10.1095/biolreprod51.3.524 7803624 (Pubitemid 24297625)
11. Retinal and choroidal microangiopathies: therapeutic opportunities. Afzal A, Shaw LC, Ljubimov AV, Boulton ME, Segal MS, Grant MB, Microvasc Res 2007 74 131 144 10.1016/j.mvr.2007.04.011 17585951 (Pubitemid 350051023)
12. Vitreous levels of interleukin-6 and vascular endothelial growth factor in macular edema with central retinal vein occlusion. Noma H, Funatsu H, Mimura T, Harino S, Hori S, Ophthalmology 2009 116 87 93 10.1016/j.ophtha.2008.09.034 19118700
13. Intravitreal levels of vascular endothelial growth factor and interleukin-6 are correlated with macular edema in branch retinal vein occlusion. Noma H, Minamoto A, Funatsu H, Tsukamoto H, Nakano K, Yamashita H, et al. Graefes Arch Clin Exp Ophthalmol 2006 244 309 315 10.1007/s00417-004-1087-4 16133018
14. Role of vasoactive factors in the pathogenesis of early changes in diabetic retinopathy. Chakrabarti S, Cukiernik M, Hileeto D, Evans T, Chen S, Diabetes Metab Res Rev 2000 16 393 407 10.1002/1520-7560(0000)9999:9999<:: AID-DMRR157>3.0.CO;2-G 11114100 (Pubitemid 32066547)
15. Effect of beta blockers and Ca2+ entry blockers on ocular vessels. Yu D-Y, Su EN, Cringle SJ, Alder VA, Yu PK, DeSantis L, Glaucoma ocular blood flow and drug treatment Kugler Publications, Amsterdam, Drance S, 1997 123 134
16. Preservation of vasoactive properties of human retinal arteries after cryopreservation. Su EN, Yu D-Y, Cringle SJ, Alder VA, Yu PK, Buckland L, Aust N Z J Ophthalmol 1998 26 59 S61 9685025
17. Histamine induces opposing vasoactive effects at different levels of the ocular vasculature. Su EN, Yu D-Y, Cringle SJ, Curr Eye Res 2005 30 205 212 10.1080/02713680590927524 15804746 (Pubitemid 40523394)
18. Vasoactivity of intraluminal and extraluminal agonists in perfused retinal arteries. Yu D-Y, Alder VA, Cringle SJ, Su EN, Yu PK, Invest Ophthalmol Vis Sci 1994 35 4087 4099 7960591 (Pubitemid 24350673)
19. Isolated preparations of ocular vasculature and their applications in ophthalmic research. Yu D-Y, Su E-N, Cringle SJ, Yu PK, Prog Retina Eye Res 2003 22 135 169 10.1016/S1350-9462(02)00044-7 (Pubitemid 36246531)
20. Vasodilation to vascular endothelial growth factor in the uterine artery of the pregnant rat is blunted by low dietary protein intake. Itoh S, Brawley L, Wheeler T, Anthony FW, Poston L, Hanson MA, Pediatr Res 2002 51 485 491 10.1203/00006450-200204000-00014 11919334 (Pubitemid 34267320)
21. VEGF-induced relaxation of pulmonary arteries is mediated by endothelial cytochrome P-450 hydroxylase. Jacobs ER, Zhu D, Gruenloh S, Lopez B, Medhora M, Am J Physiol Lung Cell Mol Physiol 2006 291 369 L377 10.1152/ajplung.00265.2004 16679379 (Pubitemid 44343712)
22. Comparison of the vasoactive effects of the docosaoid unoprostone and selected prostanoids on isolated perfused retinal arterioles. Yu D-Y, Su EN, Cringle SJ, Schoch C, Percicot CP, Lambrou GN, Invest Ophthalmol Vis Sci 2001 42 1499 1504 11381053 (Pubitemid 32520741)
23. Effect of betaxolol, timolol and nimodipine on human and pig retinal arterioles. Yu DY, Su EN, Cringle SJ, Alder VA, Yu PK, DeSantis L, Exp Eye Res 1998 67 73 81 10.1006/exer.1998.0495 9702180 (Pubitemid 28364816)
24. Severe intraocular inflammation after intravitreal injection of bevacizumab. Sato T, Emi K, Ikeda T, Bando H, Sato S, Morita S, et al. Ophthalmology 2010 117 512 516 10.1016/j.ophtha.2009.07.041 20031229
25. Is intravitreal bevacizumab use safe for AMD? Optometry. Gurwood AS, J Am Optom Assoc 2007 78 1 4
26. Pathophysiological consequences of VEGF-induced vascular permeability. Weis SM, Cheresh DA, Nature 2005 437 497 504 10.1038/nature03987 16177780 (Pubitemid 41613541)
27. Intravitreal ranibizumab may induce retinal arteriolar vasoconstriction in patients with neovascular age-related macular degeneration. Papadopoulou DN, Mendrinos E, Mangioris G, Donati G, Pournaras CJ, Ophthalmology 2009 116 1755 1761 10.1016/j.ophtha.2009.03.017 19560206
28. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. Kabbinavar F, Hurwitz HI, Fehrenbacher L, Meropol NJ, Novotny WF, Lieberman G, et al. J Clin Oncol 2003 21 60 65 10.1200/JCO.2003.10.066 12506171
29. Retinal circulatory disturbances following intracameral injection of bevacizumab for neovascular glaucoma. Yokoyama K, Choshi T, Kimoto K, Shinoda K, Nakatsuka K, Acta Ophthalmol 2008 86 927 928 10.1111/j.1755-3768.2008.01187.x 18494739
30. Ischaemic change after intravitreal bevacizumab (Avastin) injection for macular oedema secondary to non-ischaemic central retinal vein occlusion. Kim KS, Chang HR, Song S, Acta Ophthalmol 2008 86 925 927 10.1111/j.1755-3768.2008. 01175.x 18494740
31. Multiple retinal haemorrhages in diabetic retinopathy after adjunctive intravitreal bevacizumab (Avastin) with pars plana vitrectomy. Lee CS, Koh HJ, Acta Ophthalmol 2008 86 812 813 10.1111/j.1600-0420.2007.01111.x 18093262
32. Vasoactive and permeability effects of vascular endothelial growth factor-165 in the term in vitro dually perfused human placental lobule. Brownbill P, McKeeman GC, Brockelsby JC, Crocker IP, Sibley CP, Endocrinology 2007 148 4734 4744 10.1210/en.2007-0180 17640983 (Pubitemid 47481518)
33. Adrenergic nerves to the eye and its adnexia in rabbit and guinea-pig. Ehinger B, Acta Univ Lundensis 1964 2 5 23
34. Effects of beta-antagonists on contraction of bovine retinal microarteries in vitro. Hoste AM, Boels PJ, Andries LJ, Brutsaert DL, de Laey JJ, Invest Ophthalmol Vis Sci 1990 31 1231 1237 1973155 (Pubitemid 20212349)
35. Central retinal artery innervation. Laties AM, Arch Ophthalmol 1967 77 405 409 10.1001/archopht.1967.00980020407021 4960032
36. Peptidergic innervation of the retinal vasculature and optic nerve head. Ye X, Laties AM, Stone RA, Invest Ophthalmol Vis Sci 1990 31 1731 1737 1698744 (Pubitemid 20350895)
37. Biochemical evidence for cholinergic activity in retinal blood vessels. Ferrari-Dileo G, Davis EB, Anderson DR, Invest Ophthalmol Vis Sci 1989 30 473 477 2925317 (Pubitemid 19100676)
38. Retinal arterial tone is controlled by a retinal-derived relaxing factor. Delaey C, van de Voorde J, Circ Res 1998 83 714 720 10.1161/01.RES.83.7.714 9758641 (Pubitemid 28462785)
39. V: Regulatory mechanisms in the retinal and choroidal circulation. Delaey C, Van D, Ophthalmic Res 2000 32 249 256 10.1159/000055622 11015035
40. Energy requirements of glutamatergic pathways in rabbit retina. Ames A, Li YY, J Neurosci 1992 12 4234 4242 1359032
41. Energy metabolism of rabbit retina as related to function: High cost of Na+ transport. Ames A, Li YY, Heher EC, Kimble CR, J Neurosci 1992 12 840 853 1312136
42. Oxygen distribution and consumption within the retina in vascularised and avascular retinas and in animal models of retinal disease. Yu D-Y, Cringle SJ, Prog Retina Eye Res 2001 20 175 208 10.1016/S1350-9462(00)00027-6 (Pubitemid 32153715)
43. Intraretinal oxygen distrubution in the monkey retina and the response to systemic hyperoxia. Yu D-Y, Cringle SJ, Su E-N, Invest Ophthalmol Vis Sci 2005 46 4728 4733 10.1167/iovs.05-0694 16303972 (Pubitemid 44264577)
44. Microscopic structure of the retina and vasculature in the human eye. Yu DY, Yu PK, Balaratnasingam C, Cringle SJ, Su EN, Microscopy: Science, Technology, Applications and Education Formatex Research Center, Badajoz, Méndez-Vilas A, Díaz J, 2 2010 867 875
45. Response of Retinal Vessels and Retrobulbar Hemodynamics to Intravitreal Anti-VEGF Treatment in Eyes with Branch Retinal Vein Occlusion. Sacu S, Pemp B, Weigert G, Matt G, Garhofer G, Pruente C, et al. Invest Ophthalmol Vis Sci 2011 52 3046 3050 10.1167/iovs.10-5842 21051706
46. Regulation of microvascular permeability by vascular endothelial growth factors. Bates DO, Hillman NJ, Williams B, Neal CR, Pocock TM, J Anat 2002 200 581 597 10.1046/j.1469-7580.2002.00066.x 12162726 (Pubitemid 34823050)